| 摘要 |
A combination therapy is described comprising the CYP-metabolized compound Simvastatin and the growth hormone releasing factor (GRF) analogue (hexenoyl trans-3)hGRF(l-44)NH2 (tesamorelin), for the treatment of HIV- associated lipodystrophy. Human growth hormone may modulate cytochrome P450 (CYP) enzyme activity. Therefore, the potential impact of tesamorelin on CYP3A activity was investigated by examining its effect on the pharmacokinetics (PK) of simvastatin ( a CYP3A-substrate), a drug that is potentially administered concomitantly with tesamorelin. This study showed that the impact of tesamorelin on CYP3 A activity appears to be minimal. Simvastatin may be co-administered with tesamorelin, without changing the dosing regimen.
|
